Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 12, 2026

China controls 90% of rare-earth processing — now a $204 million US investment in France aims to change that

View original at finance.yahoo.com
China controls 90% of rare-earth processing — now a $204 million US investment in France aims to change that Joe Raedle/Getty Images Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • China controls about 90% of global rare-earth processing and refining capacity

    60% confidence
  • Despite the name, rare earths aren't especially rare — the challenge is processing them

    60% confidence
  • Gold prices are at near-record highs driven by investor concerns about inflation, government debt, geopolitical tensions and market volatility

    60% confidence
  • The USA Rare Earth investment aligns with US government efforts to build supply chains outside of China and secure access to materials critical to national security and advanced manufacturing

    60% confidence
  • The France expansion project could create more than 300 jobs

    60% confidence
  • China controls roughly 70% of global rare-earth mining production

    60% confidence
  • The France expansion may receive support from the French government

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com
China controls 90% of rare-earth processing — now a $204 million US investment in France aims to change that — Source | Via News | ViaNews Market